Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.01.30
Relationship between DAMPs/PAMPs and pathogenesis of STAM mice
Today, we would like to share with you the correlation between our proprietary STAMTM model for NASH-HCC, and DAMPs/PAMPs related factors. One of the factors that cause inflammation and fibrosis is damage-associated molecule patterns (DAMPs), which are released when tissues and cells are damaged. Pathogen-associated molecule patterns (PAMPs) are known to be released by…
2025.01.30
Fibrosis-related factors and pathogenesis of STAM mice
Today, we would like to introduce the correlation between our proprietary STAMTM model and fibrosis-related factors such as HSP47. NASH is a progressive liver disease that differs from simple fatty liver in that it has a risk of developing liver fibrosis and eventually liver cancer. As the later stages of liver fibrosis, including cirrhosis…
2025.01.30
Wnt/β-catenin in STAM: How does it correlate to human liver cancer?
We would like to share with you the HCC-related gene expression data of our proprietary MASH-HCC model (STAMTM). The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection. By virtue of recent advances in treatment methods, the number of patients with HCC caused by these infections is expected…
2025.01.29
Potential MASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our MASH model (STAMTM model). Hepatocellular ballooning is a key finding distinguishing MASH from simple steatosis in terms of MASH diagnosis. CK-18 (cytokeratin 18) is known as one of the promising non-invasive biomarkers and was also recommended at the AASLD-FDA joint workshop…
2025.01.29
Fibrosis markers in the STAM model
We would like to introduce a non-invasive fibrosis marker. Currently, the most reliable method for MASH diagnosis is histological evaluation through liver biopsy. However, various drawbacks of the liver biopsy method, such as sampling error and burden to patients, have spurred the research and development of non-invasive early-diagnosis markers. One of these potential…
2025.01.29
Introduction of DDC-Induced Cholestatic Liver Disease Mouse Model
We would like to introduce mice model of primary sclerosing cholangitis (PSC), as well as 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mice model. PSC PSC is a chronic bile duct disorder characterized by plaque inflammation, fibrosis, and stricture of the bile ducts, which may progress to the terminal stage requiring liver transplantation. Ursodeoxycholic acid is a potent treatment that…
2025.01.29
Pre-clinical studies for Cholestatic Liver Diseases: Bile Duct Ligation model
We would like to share with you about our Bile duct ligation (BDL) model, known as a disease model mice for cholestatic liver disease. This model reproduces the pathological features of cholestatic liver disease, which leads to acute liver injury followed by liver inflammation and severe fibrosis. It is a useful model for…
2025.01.29
Positive control for CCl4 mouse model
We would like to introduce our carbon tetrachloride (CCl4)-induced liver fibrosis model, which is a widely used and reliable animal model of cirrhosis. The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. While our STAM™ model develops mild liver fibrosis, the CCl4 model develops severe cirrhosis-like…
2025.01.29
Proteinuria in the Adriamycin model
When discussing our mouse models of chronic kidney disease (CKD), we are often asked about proteinuria as a urinary marker of kidney damage. As an important marker used in clinical trials, it’s also an important endpoint to look at in non-clinical research. Proteinuria data in the Adriamycin model Above is the time-course data of…
2025.01.29
Drug efficacy evaluation study for fibrotic diseases involving multiple organs
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and after conducting pre-clinical studies in mice at our company, submitted the results of their research to Nature Biotechnology. Ren et al., Nat Biotechnol., 2024 This article identifies TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic…
We can help you advance your research.